HUGE: FSD Pharma Company Value to Net Income

FSD Pharma Inc. generates revenue by bringing neurotherapies to market, including treatments for depression and Alzheimer's and Parkinson's diseases; the shares of FSD Pharma Inc. (HUGE) shown on this price chart on GURU.Markets have a -0.30 indicator. The safety of neurobiology trials is ensured by strict monitoring of reagent transportation. The business is currently focusing on organic growth, divesting non-core assets and cutting costs due to a liquidity shortage.

FSD Pharma Inc. - HUGE P/E Multiple (period 07/04/2022 - 08/15/2024)

Analytical breakdowns for FSD Pharma Inc.

- price and consensus price forecast:

Stock Price FSD Pharma, Inc.|HUGE - Consensus Target

- market capitalization information:

Market Value FSD Pharma Inc.|HUGE - Total Company Value

- balance sheet net asset value indicators:

Equity per Share FSD Pharma|HUGE - Book Capitalization|Market-to-Book Ratio fsdpharma.com|HUGE - Cumulative Company Assets

- company liabilities and liquidity data:

- financial results and valuation multiples details:

HUGE - Net Profit|Projected Net Profit FSD Pharma Inc.|HUGE - Price to Earnings Ratio|Projected Price to Earnings Ratio FSD Pharma, Inc.|HUGE - PEG Multiple|Company Value to Operating Income Before Depreciation Ratio FSD Pharma Inc.|HUGE - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters FSD Pharma|HUGE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months fsdpharma.com|HUGE - Net earnings per share growth this year|Expected earnings per share trend next year FSD Pharma Inc.

Comprehensive company analysis:HUGE (FSD Pharma, Inc.)

For the biotech sector, the P/E ratio serves as a key indicator of market expectations regarding the future earnings of FSD Pharma Inc. (HUGE). This ratio is calculated as the market price per share divided by net earnings per share, reflecting the cost of one dollar of earnings in the business's current P/E. High values signal inflated expectations, while low values indicate undervaluation. The company's lack of debt obligations minimizes the risk of collapse during periods of volatility for this metric. A clean balance sheet ensures the autonomy of CNS developments regardless of market quotes.

Analysis of competing companies